I-Mab Biopharma is a biotech company focused on the development of biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. Its research and development capabilities encompass discovery, translational medicine, chemistry, manufacturing and controls (CMC) for biologics, pre-clinical development and clinical development, as well as business development functions. I-Mab Biopharma's pipeline of clinical and pre-clinical stage drug candidates is driven by the Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D capabilities and global partnerships.